Insights on mechanisms of clonal evolution in chronic neutrophilic leukemia on ruxolitinib therapy

Ryan C. Stoner; Richard D. Press; Julia E. Maxson; Jeffrey W. Tyner; Kim Hien T. Dao

doi:10.1038/s41375-019-0688-1

Insights on mechanisms of clonal evolution in chronic neutrophilic leukemia on ruxolitinib therapy

Ryan C. Stoner, Richard D. Press, Julia E. Maxson, Jeffrey W. Tyner, Kim Hien T. Dao

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	1684-1688
Number of pages	5
Journal	Leukemia
Volume	34
Issue number	6
DOIs	https://doi.org/10.1038/s41375-019-0688-1
State	Published - Jun 1 2020

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-019-0688-1

Cite this

@article{f04d8bca6919455e870676e29908af6b,

title = "Insights on mechanisms of clonal evolution in chronic neutrophilic leukemia on ruxolitinib therapy",

author = "Stoner, {Ryan C.} and Press, {Richard D.} and Maxson, {Julia E.} and Tyner, {Jeffrey W.} and Dao, {Kim Hien T.}",

note = "Funding Information: Acknowledgements This work was supported in part by Incyte, Inc. KHD served on advisory board meetings and received compensation from Incyte. JWT received grants from the National Cancer Institute (1U01CA217862, 1U54CA224019, and 1R01CA183947), the V Foundation for Cancer Research, and the Gabrielle{\textquoteright}s Angel Foundation for Cancer Research. JWT has received research support from Agios, Aptose, Array, AstraZeneca, Constellation, Genentech, Gilead, Incyte, Janssen, Seattle Genetics, Syros, and Takeda; JWT is a cofounder of Vivid Biosciences.",

year = "2020",

month = jun,

day = "1",

doi = "10.1038/s41375-019-0688-1",

language = "English (US)",

volume = "34",

pages = "1684--1688",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "6",

}

TY - JOUR

T1 - Insights on mechanisms of clonal evolution in chronic neutrophilic leukemia on ruxolitinib therapy

AU - Stoner, Ryan C.

AU - Press, Richard D.

AU - Maxson, Julia E.

AU - Tyner, Jeffrey W.

AU - Dao, Kim Hien T.

N1 - Funding Information: Acknowledgements This work was supported in part by Incyte, Inc. KHD served on advisory board meetings and received compensation from Incyte. JWT received grants from the National Cancer Institute (1U01CA217862, 1U54CA224019, and 1R01CA183947), the V Foundation for Cancer Research, and the Gabrielle’s Angel Foundation for Cancer Research. JWT has received research support from Agios, Aptose, Array, AstraZeneca, Constellation, Genentech, Gilead, Incyte, Janssen, Seattle Genetics, Syros, and Takeda; JWT is a cofounder of Vivid Biosciences.

PY - 2020/6/1

Y1 - 2020/6/1

UR - http://www.scopus.com/inward/record.url?scp=85076454748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076454748&partnerID=8YFLogxK

U2 - 10.1038/s41375-019-0688-1

DO - 10.1038/s41375-019-0688-1

M3 - Article

C2 - 31844143

AN - SCOPUS:85076454748

SN - 0887-6924

VL - 34

SP - 1684

EP - 1688

JO - Leukemia

JF - Leukemia

IS - 6

ER -

Insights on mechanisms of clonal evolution in chronic neutrophilic leukemia on ruxolitinib therapy

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this